GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance

Funding Cycle:

2024-2025

Name:

Josefine Krüger

Type of Award:

Career Development Award

Home Institution:

Charité Universitätsmedizin, Berlin, Germany

Host Institution:

Columbia University

Description

RAS mutations in multiple myeloma lead to increased germinal center kinase (GCK) expression, presenting a potential new therapeutic target. Inhibiting GCK (GCKi) has shown to reduce myeloma cell proliferation in both in vitro and in vivo models (Li et al., Blood, 2021). Additionally, unlike IMiDs, GCKi promotes the proteasomal degradation of IKZF1/3 through a pathway independent of cereblon. Our goal in this IMS-funded project is to uncover the mechanism by which GCKi regulates IKZF1 degradation and increase the efficacy of GCKI as therapeutic approach. This project aims to introduce a personalized therapeutic strategy for RAS-mutated multiple myeloma.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

See All of the Member Benefits

Become a Member Today